Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Commensal Bacteria Strains
- Development stage
- Unknown
- Lead developer
- University of Chicago
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Commensal Bacteria Strains (University of Chicago) is an investigational live biotherapeutic product (LBP) consisting of defined consortia of commensal bacterial strains. Developed by the University of Chicago's Duchossois Family Institute (DFI), the therapy is designed to treat severe liver diseases, including cirrhosis and liver failure, by addressing gut dysbiosis. The product comprises capsules containing combinations of 17 bacterial strains (with specific consortia of 8 strains used in clinical trials) intended to restore the gut microbiome's composition and metabolic function. Specifically, the therapy targets the restoration of fecal metabolite levels, such as butyrate and deoxycholic acid, which are often depleted in patients with chronic liver disease. It is manufactured in an in-house cGMP facility and is currently being evaluated in the Phase 1b MARCO (Microbiota Augmentation in Liver Disease) adaptive clinical trial to assess safety and tolerability in hospitalized patients.
- Other names
- Commensal ConsortiaDefined commensal bacterial consortiaMicrobiota Augmentation to Reestablish Commensal Organisms
Beyond the preview
Go deeper on Commensal Bacteria Strains.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Commensal Bacteria Strains.